PLA2G7 and fungal infectious disease: During the discovery and initial validation of the PLAC8 and PLA2G7 biomarkers [22], patients with a broad range of co-morbidities were examined, including septic patients with confirmed bacterial, viral, fungal infections and malignancies, and non-septic patients with non-infectious systemic inflammation of varying etiologies.